Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS

Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS

Abstract: Higher-risk myelodysplastic syndrome (HR-MDS) with RARA gene overexpression is a subset of patients (pts) with an actionable target for tamibarotene, an oral and a selective retinoic acid receptor-α (RAR-α) agonist. Tamibarotene with azacitidine (AZA) showed complete remission (CR) rates i...

Full description

Saved in:
Bibliographic Details
Main Authors: Amy E. DeZern, Sylvain Thepot, Stephane de Botton, Andrea Patriarca, Dries Deeren, Jose-Miguel Torregrossa-Diaz, Giovanni Marconi, Teresa Bernal, Juan Bergua Burgues, Blanca Xicoy, Anna Jonášová, Amer M. Zeidan, Sophie Dimicoli-Salazar, Célestine Simand, David Valcarcel, Maria Diez Campelo, Wanxing Chai-Ho, Lalit Saini, Alice Garnier, Klaus Geissler, Yishai Ofran, Zsolt Nagy, Pramila Krishnamurthy, Michael Lübbert, Grzegorz Basak, Hetty E. Carraway, David A. Sallman, Uma Borate, Valeria Santini, Victoria Campbell, Pierre Fenaux, Thorsten Braun, Francesco Lanza, Jan Maciej Zaucha, David A. Roth, Sofia Paul, Pourab Roy, Michael J. Kelly, Angela Volkert, Jaime Chisholm, Tanya Abdul Malak, Virginia M. Klimek, Thomas Cluzeau
Format: Article
Language:English
Published: Elsevier 2025-08-01
Series:Blood Advances
Online Access:http://www.sciencedirect.com/science/article/pii/S2473952925002721
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items